Advertisement

Rediscovering therapies for hypertrophic cardiomyopathy

Published:November 11, 2022DOI:https://doi.org/10.1016/j.ijcard.2022.11.014
      Hypertrophic cardiomyopathy (HCM) is a remarkably heterogeneous disease comprised of numerous subgroups of patients [
      • Veselka J.
      • Anavekar N.S.
      • Charron P.
      Hypertrophic obstructive cardiomyopathy.
      ,
      • Bonaventura J.
      • Polakova E.
      • Vejtasova V.
      • Veselka J.
      Genetic testing in patients with hypertrophic cardiomyopathy.
      ]. Although HCM is not a uniformly progressive illness, the symptoms may occur or worsen at virtually any age, most frequently in midlife. HCM has now transformed into a contemporary, highly treatable condition with effective options that alter natural history along specific adverse pathways [
      • Rowin E.J.
      • Maron M.S.
      • Chan R.H.
      • et al.
      Interaction of adverse disease related pathways in hypertrophic cardiomyopathy.
      ].
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to International Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Veselka J.
        • Anavekar N.S.
        • Charron P.
        Hypertrophic obstructive cardiomyopathy.
        Lancet. 2017; 389: 1253-1267
        • Bonaventura J.
        • Polakova E.
        • Vejtasova V.
        • Veselka J.
        Genetic testing in patients with hypertrophic cardiomyopathy.
        Int. J. Mol. Sci. 2021; 22: 10401
        • Rowin E.J.
        • Maron M.S.
        • Chan R.H.
        • et al.
        Interaction of adverse disease related pathways in hypertrophic cardiomyopathy.
        Am. J. Cardiol. 2017; 120: 2256-2264
        • Maron B.J.
        • Desai M.Y.
        • Nishimura R.A.
        • et al.
        Management of hypertrophic cardiomyopathy.
        J. Am. Coll. Cardiol. 2022; 79: 390-414
        • Scirica B.M.
        • Morrow D.A.
        • Hod H.
        • et al.
        Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non–ST-segment–elevation acute coronary syndrome.
        Circulation. 2007; 116: 1647-1652
        • Lei M.
        • Wu L.
        • Terrar D.A.
        • Huang C.L.H.
        Modernized classification of cardiac antiarrhythmic drugs.
        Circulation. 2018; 138: 1879-1896
        • Coppini R.
        • Ferrantini C.
        • Yao L.
        • et al.
        Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy.
        Circulation. 2013; 127: 575-584
        • Gentry J.L.
        • Mentz R.J.
        • Hurdle M.
        • Wang A.
        Ranolazine for treatment of angina or dyspnea in hypertrophic cardiomyopathy patients (RHYME).
        J. Am. Coll. Cardiol. 2016; 68: 1815-1817
        • Olivotto I.
        • Camici P.G.
        • Merlini P.A.
        • et al.
        Efficacy of ranolazine in patients with symptomatic hypertrophic cardiomyopathy.
        Circ. Heart Fail. 2018; 11e004124
        • Argirò A.
        • Zampieri M.
        • Dei L.
        • et al.
        Safety and efficacy of ranolazine in hypertrophic cardiomyopathy: real-world experience in a National Referral Center.
        Int. J. Cardiol. 2022; 0https://doi.org/10.1016/j.ijcard.2022.10.014

      Linked Article